These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7855389)
1. [Interferon-alpha in the treatment of myeloproliferative syndromes]. Ballarino P; Castello G; Lerza R Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389 [TBL] [Abstract][Full Text] [Related]
2. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders]. Skotnicki AB; Wolska-Smoleń T Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197 [TBL] [Abstract][Full Text] [Related]
3. [Use of interferon in the treatment of chronic myeloproliferative disorders]. Robak T Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870 [TBL] [Abstract][Full Text] [Related]
4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S; Stock W; Godwin J; Fisher SG Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Elliott MA; Tefferi A Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205 [TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Hasselbalch HC Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152 [TBL] [Abstract][Full Text] [Related]
7. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM; Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. Litam PP; Landaw SA; Zamkoff KW Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266 [TBL] [Abstract][Full Text] [Related]
10. Transplant decision-making strategies in the myeloproliferative disorders. Fruchtman SM Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880 [TBL] [Abstract][Full Text] [Related]
12. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia]. Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464 [TBL] [Abstract][Full Text] [Related]
13. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Kantarjian HM; Talpaz M Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099 [TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera]. Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805 [TBL] [Abstract][Full Text] [Related]
16. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158 [TBL] [Abstract][Full Text] [Related]
17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
19. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Hasselbalch HC Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528 [TBL] [Abstract][Full Text] [Related]
20. Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]